



06-01-07

IFM1/6257

Express Mail No. EB 132603464 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No.: 7,214,683

Issued: May 8, 2007

Application of: Aberg *et al.*

Confirmation No.: 9369

Application No.: 09/039,260

Group Art Unit: 1625

Filed: March 16, 1998

Examiner: Chang, C.

For: COMPOSITIONS OF
DESCARBOETHOXYLORATADINE

Attorney Docket No.: 4821-306
(JD 208423-999305)

Petition Under 37 C.F.R. § 1.182

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

06/04/2007 BABRAHA1 00000004 503013 7214683
01 FC:1462 400.00 DA

Sir:

It is respectfully requested that the terminal disclaimer submitted during prosecution of U.S. Application No. 09/039,260, which mentioned only Sepracor as assignee, be replaced with the terminal disclaimer submitted herewith. The basis for grant of this petition and provision for the required petition fee are provided below. Separate provision for the terminal disclaimer fee is also provided herein.

This petition is being concurrently submitted with a Petition Under 37 C.F.R. § 3.81(b) and a Request for Certificate of Correction to clarify that the above-identified patent is assigned to both Sepracor Inc. ("Sepracor") and University of Massachusetts.

Basis for Grant of Petition

It has recently been brought to the attention of the Patentees that an incorrect statement was inadvertently made in connection with a terminal disclaimer submitted March 17, 2006 in connection with U.S. Application No. 09/039,260. That terminal disclaimer states that Sepracor "is the assignee of the entire right, title, and interest in and to" the above-identified patent and U.S. Patent No. 5,595,997 (collectively "Patents"). Although the entire right, title, and interest in and to Patents

were originally assigned to Sepracor, Sepracor subsequently assigned one half of its entire right, title, and interest in and to the Patents to University of Massachusetts, Worcester, MA. The second assignment was recorded at the Patent Office at Reel 008754, Frame 0866, a copy of which is attached hereto as **Exhibit A**. Even though the March 17, 2006 terminal disclaimer was reviewed and approved by the Patent Office, a corrected terminal disclaimer which complies with 37 C.F.R. §§ 1.321 and 3.73, and which is executed by both Sepracor and University of Massachusetts, is submitted herewith.

Based on the foregoing, Patentees wish to correct the record to reflect that the Patents are jointly owned by Sepracor and University of Massachusetts. Consequently, it is respectfully requested that the March 17, 2006 terminal disclaimer be replaced with the terminal disclaimer submitted herewith. It is further requested that the terminal disclaimer executed by both assignees be placed in the above-identified file.


Conclusion

For the foregoing reasons, it is respectfully requested that the terminal disclaimer executed by both assignees be accepted, and that this terminal disclaimer be entered into the record of the above-identified patent file-wrapper.

A fee of \$ 400.00 is believed due for this submission. Please charge this and any other required fees to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date May 30, 2007



Hoon Chbi (Ltd. Recog. No.)
JONES DAY

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
12265 El Camino Real, Suite 200
San Diego, CA 92130
(858) 314-1200

COPY

Express Mail No. EB 132603464 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No.: 7,214,683

Issued: May 8, 2007

Application of: Aberg *et al.*

Confirmation No.: 9369

Application No.: 09/039,260

Group Art Unit: 1625

Filed: March 16, 1998

Examiner: Chang, C.

For: COMPOSITIONS OF
DESCARBOETHOXYLORATADINE

Attorney Docket No.: 4821-306
(JD 208423-999305)

Petition Under 37 C.F.R. § 1.182

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the terminal disclaimer submitted during prosecution of U.S. Application No. 09/039,260, which mentioned only Sepracor as assignee, be replaced with the terminal disclaimer submitted herewith. The basis for grant of this petition and provision for the required petition fee are provided below. Separate provision for the terminal disclaimer fee is also provided herein.

This petition is being concurrently submitted with a Petition Under 37 C.F.R. § 3.81(b) and a Request for Certificate of Correction to clarify that the above-identified patent is assigned to both Sepracor Inc. ("Sepracor") and University of Massachusetts.

Basis for Grant of Petition

It has recently been brought to the attention of the Patentees that an incorrect statement was inadvertently made in connection with a terminal disclaimer submitted March 17, 2006 in connection with U.S. Application No. 09/039,260. That terminal disclaimer states that Sepracor "is the assignee of the entire right, title, and interest in and to" the above-identified patent and U.S. Patent No. 5,595,997 (collectively "Patents"). Although the entire right, title, and interest in and to Patents

were originally assigned to Sepracor, Sepracor subsequently assigned one half of its entire right, title, and interest in and to the Patents to University of Massachusetts, Worcester, MA. The second assignment was recorded at the Patent Office at Reel 008754, Frame 0866, a copy of which is attached hereto as **Exhibit A**. Even though the March 17, 2006 terminal disclaimer was reviewed and approved by the Patent Office, a corrected terminal disclaimer which complies with 37 C.F.R. §§ 1.321 and 3.73, and which is executed by both Sepracor and University of Massachusetts, is submitted herewith.

Based on the foregoing, Patentees wish to correct the record to reflect that the Patents are jointly owned by Sepracor and University of Massachusetts. Consequently, it is respectfully requested that the March 17, 2006 terminal disclaimer be replaced with the terminal disclaimer submitted herewith. It is further requested that the terminal disclaimer executed by both assignees be placed in the above-identified file.


Conclusion

For the foregoing reasons, it is respectfully requested that the terminal disclaimer executed by both assignees be accepted, and that this terminal disclaimer be entered into the record of the above-identified patent file-wrapper.

A fee of \$ 400.00 is believed due for this submission. Please charge this and any other required fees to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date May 30, 2007



Hoon Chbi (Ltd. Recog. No.)
JONES DAY

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
12265 El Camino Real, Suite 200
San Diego, CA 92130
(858) 314-1200

Exhibit A



10-27-1997

EXPRESS MAIL NO.: 706866268534



ET

100557585

Attorney Docket Number

4821-206

TO THE HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS

Box Assignment
Washington, DC 20231

MR9 10-8-97

Please record the attached original documents or copy thereof.

1. Name of conveying parties: Sepacor, Inc.		2. Name and address of receiving party: Name <u>University of Massachusetts</u> Address <u>18 Tremont Street</u> <u>Boston, Massachusetts 02108</u> Country (if other than USA):	
Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other			
Execution Date: <u>September 12, 1997</u>			
4. Application number(s) or patent number(s). If this document is being filed together with a new application, the execution date of the application is: A. Patent Application No. <u>08/366,651, filed December 10, 1994</u> B. Patent No.(s) <u>5,595,997</u> Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
5. Name and address of party to whom correspondence concerning document should be mailed: PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, NY 10036		6. Number of applications and patents involved: <u>1</u>	
		7. Total fee (37 CFR 3.41) <u>\$ 40.00</u> Please charge to the deposit account listed in Section 8	
		8. Deposit account number: <u>16-1150</u>	
DO NOT USE THIS SPACE			
9. Statement and signature <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i> <u>Stanton T. Lawrence, III</u> <u>15,736</u> <u>Signature</u> <u>October 8, 1997</u> Name of Person Signing Reg. No. Signature Date <u>3</u> Total number of pages including cover sheet			

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignment
Washington, D.C. 20231

10/23/1997 JSHARAZZ 00000027 DAW:161150 08366651
Sale Ref: 00000028 DAW: 161150 08366651
01 FC:SAI 40.00 CH

PATENT
REF: 8754 FRANKIE 0866
PENNY 0866

ASSIGNMENT

WHEREAS, the inventors, A.K. Gunnar Aberg, John R. McCullough and Emil R. Smith, citizens of Sweden, the United States and the United States, respectively, by an Assignment executed March 1, 1995, which was recorded in the United States Patent and Trademark Office on March 6, 1995, at Reel No. 7432, Frame No. 712, have assigned their full and exclusive right in and to the invention set forth in U.S. Application Serial No. 08/366,651, filed December 30, 1994 entitled METHODS AND COMPOSITIONS FOR TREATING ALLERGIC RHINITIS AND OTHER DISORDERS USING DESCARBOETHOXYLORATADINE to Sepracor Inc., having a principle place of business at 111 Locke Drive, Marlborough, Massachusetts 01752, a Delaware corporation ("Assignor"); and

WHEREAS, Assignor has taken the entire right, title and interest in the above-mentioned patent application; and

WHEREAS, University of Massachusetts, 18 Tremont Street, Boston, Massachusetts 02108 ("Assignee") desires to acquire an undivided one-half (1/2) interest in said invention; and WHEREAS, Assignor is willing to assign such an interest therein to Assignee while Assignor retains an undivided one-half (1/2) interest.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign, sell, and transfer to Assignee, its successors, assigns and legal representatives, an undivided one-half (1/2) interest in said invention and patent application, and any continuation, continuation-in-part, division, substitute, reissue, or extension thereof and any patents issuing thereon properly naming Emil R. Smith as an inventor.

PATENT
REF.: 8754 FRAME: 0868